Can a withdrawn myeloma drug make a comeback with a gentler schedule?
Disease control
Not yet recruiting
This study tests whether the drug belantamab mafodotin, given every 6 weeks alongside a steroid, can be safely used in community clinics for patients with relapsed or refractory multiple myeloma. The drug was previously removed from the market after a confirmatory study failed, b…
Phase 2 • Sponsor: Cristiana Costa Chase, DO • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC